IONS - Ionis Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
58.76
+1.35 (+2.35%)
At close: 4:00PM EST

58.76 0.00 (0.00%)
After hours: 4:55PM EST

Stock chart is not supported by your current browser
Previous Close57.41
Open57.52
Bid52.00 x 1100
Ask60.00 x 800
Day's Range57.25 - 58.79
52 Week Range39.07 - 60.92
Volume414,533
Avg. Volume848,965
Market Cap8.084B
Beta (3Y Monthly)1.94
PE Ratio (TTM)N/A
EPS (TTM)-0.51
Earnings DateFeb 27, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est55.79
Trade prices are not sourced from all markets
  • Analysts Estimate Ionis Pharmaceuticals (IONS) to Report a Decline in Earnings: What to Look Out for
    Zacks2 days ago

    Analysts Estimate Ionis Pharmaceuticals (IONS) to Report a Decline in Earnings: What to Look Out for

    Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Is Moderna a Buy?
    Motley Fool8 days ago

    Is Moderna a Buy?

    The biggest-ever biotech IPO heralds enormous promise for a new class of medicines.

  • PR Newswire10 days ago

    Ionis Pharmaceuticals to Hold 2018 Financial Results Webcast

    CARLSBAD, Calif., Feb. 13, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS) announced today that it will host a live webcast on Wednesday, February 27th at 11:30 a.m. Eastern Time to discuss its 2018 financial results and report on pipeline and business progress. As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, proprietary antisense technology platform with the potential to treat diseases where no other therapeutic approaches have proven effective.

  • Is Ionis Pharmaceuticals, Inc.’s (NASDAQ:IONS) CEO Pay Fair?
    Simply Wall St.10 days ago

    Is Ionis Pharmaceuticals, Inc.’s (NASDAQ:IONS) CEO Pay Fair?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Stan Crooke became the CEO of IonisRead More...

  • Markit15 days ago

    See what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.

    Ionis Pharmaceuticals Inc NASDAQ/NGS:IONSView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for IONS with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding IONS totaled $2.06 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Biogen Looks to 2020
    Motley Fool23 days ago

    Biogen Looks to 2020

    2018 wasn't too bad, but don't expect much in 2019

  • Benzinga23 days ago

    Ionis Wins Price Target Hike On Partner Biogen's Guidance

    Ionis Pharmaceuticals Inc (NASDAQ: IONS )'s partner Biogen Inc (NASDAQ: BIIB ) reported fourth-quarter results Wednesday before the market open, revealing that sales of the spinal muscular atrophy treatment ...

  • Has Ionis Pharmaceuticals (IONS) Outpaced Other Medical Stocks This Year?
    Zacks25 days ago

    Has Ionis Pharmaceuticals (IONS) Outpaced Other Medical Stocks This Year?

    Is (IONS) Outperforming Other Medical Stocks This Year?

  • PR Newswire26 days ago

    First Patient Enrolled in Pivotal Study of RG6042 (IONIS-HTT Rx) for People with Huntington's Disease

    CARLSBAD, Calif., Jan. 28, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS), the leader in antisense therapeutics, today announced that its partner Roche, also known as Genentech in the United States, has enrolled the first patient in a pivotal study of RG6042 (IONIS-HTTRx) for people living with symptoms of Huntington's disease (HD), a hereditary neurodegenerative disorder for which there is currently no approved disease-modifying treatment. RG6042 is the first therapy in pivotal trials designed to target the underlying cause of HD by reducing production of the toxic mutant huntingtin protein (mHTT). Ionis has earned a $35 million milestone payment for the initiation of the study.

  • Is This 'Perennial' Innovator Making A Comeback Among Biotech Stocks?
    Investor's Business Daily29 days ago

    Is This 'Perennial' Innovator Making A Comeback Among Biotech Stocks?

    Shares of Ionis have climbed 6.3% this year. The biotech is on track to enter four drugs into pivotal clinical studies this year, an analyst said in a bullish note on Ionis.

  • Ironwood Commences Phase I Study on IW-6463 for CNS Disorders
    Zacks29 days ago

    Ironwood Commences Phase I Study on IW-6463 for CNS Disorders

    Ironwood (IRWD) begins a phase I study on CNS-penetrant soluble guanylate cyclase stimulator, IW-6463, for treating severe CNS disorders.

  • 4 Defensive Stocks to Buy Amid Shutdown and Brexit
    Zackslast month

    4 Defensive Stocks to Buy Amid Shutdown and Brexit

    Defensive equities could ride out market unpredictability.

  • Pfizer Gets FDA's Priority Review for Rare Disease Candidate
    Zackslast month

    Pfizer Gets FDA's Priority Review for Rare Disease Candidate

    FDA grants priority review to Pfizer's (PFE) regulatory filing looking for approval of pipeline candidate, tafamidis to treat transthyretin amyloid cardiomyopathy.

  • This Biotech Stock Plunged On Its Looming Rivalry With Pfizer
    Investor's Business Dailylast month

    This Biotech Stock Plunged On Its Looming Rivalry With Pfizer

    Alnylam dipped Monday after the FDA agreed to review an amyloidosis treatment from Pfizer in just six months. Pfizer's drug would treat patients with abnormal protein building in the heart.

  • 3 Top Biotech Stocks to Buy in January
    Motley Foollast month

    3 Top Biotech Stocks to Buy in January

    Adding these biotech stocks to your portfolio could be a great New Year's resolution for aggressive investors.

  • Cannabis, Migraines, Gene-Silencing: FDA Approvals Hit High Note In 2018
    Investor's Business Daily2 months ago

    Cannabis, Migraines, Gene-Silencing: FDA Approvals Hit High Note In 2018

    The Food and Drug Administration approved 59 new drugs in 2018 — hitting at least a four-year record — though fewer biologic drugs passed muster. There were also 17 biologic drugs approved.

  • PR Newswire2 months ago

    Ionis Pharmaceuticals to Present at 37th Annual J.P. Morgan Healthcare Conference

    CARLSBAD, Calif., Jan. 2, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS), the leader in antisense therapeutics, today announced that Management will present a Company overview at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 4:00 p.m. PT in San Francisco, CA. A live audio webcast of the presentation will be available on the Investors & Media section of the Company's website, www.ionispharma.com. As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, proprietary antisense technology platform with the potential to treat diseases where no other therapeutic approaches have proven effective.

  • MoneyShow2 months ago

    Top Picks 2019- Ionis Pharmaceuticals IONS

    Ionis Pharmaceuticals (IONS) is my top pick as a conservative biotech recommendation in 2019; the company represents a unique blend with an exciting and broad pipeline of drug development candidates balanced by revenue generation from approved drugs, observes John McCamant, editor of The Medical Technology Stock Letter.

  • 4 of the Fastest Growing Biotech Stocks in 2019
    Motley Fool2 months ago

    4 of the Fastest Growing Biotech Stocks in 2019

    Earnings per share will more than double for each of these specialty drugmakers.

  • Spectrum Pharmaceuticals: Earnings Trends and Recent Developments
    Market Realist2 months ago

    Spectrum Pharmaceuticals: Earnings Trends and Recent Developments

    In the first nine months of 2018, Spectrum Pharmaceuticals (SPPI) reported a net income and diluted EPS of -$70.8 million and -$0.69, respectively—compared to -$62.7 million and -$0.78 in the same period the previous year.

  • Why Gene Therapy Is More Cost Effective Than Biogen's Approved Drug
    Investor's Business Daily2 months ago

    Why Gene Therapy Is More Cost Effective Than Biogen's Approved Drug

    An experimental gene therapy from Novartis, called Zolgensma, is more cost effective than Biogen and Ionis Pharmaceuticals' treatment for a muscle-wasting disease, experts said this week.

  • MarketWatch2 months ago

    Ionis Pharmaceuticals outlines CEO succession plan

    Ionis Pharmaceuticals Inc. said late Thursday that Brett Monia will succeed Stanley Crooke as chief executive in a year. The drug development company said Monia, who is the current chief operating officer, will become CEO in January 2020, and Crooke will become executive chairman of Ionis's board. Shares of Ionis, which were flat after hours, had closed down 2.1% at $49.78 in regular trading Thursday.